What they were paid
4D Molecular Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $65,000 | $0 | $70,000 | $0 | $135,000 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 4D Molecular Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001140361-26-017427, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY20254D Molecular Therapeutics pays directors a $40,000 cash retainer and $70,000 in Options.
Committees
FY2025 · as the proxy prints themAudit · Nominating/Governance · Science and Technology (Chair)
The rest of the 4D Molecular Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| David Kirn, M.D | Director | $0 |
| Glenn Sblendorio | Independent Director | $0 |
| Jacob Chacko, M.D., MBA | Independent Director | $135,000 |
| John F. Milligan, Ph.D | Chair of the Board | $255,000 |
| Nancy Miller-Rich | Independent Director | $122,500 |
| Shawn Cline Tomasello, MBA | Independent Director | $132,500 |
| Susannah Gray, MBA | Independent Director | $135,000 |
The full 4D Molecular Therapeutics compensation record
free company briefThis page is one director within 4D Molecular Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat